Physician profile
Ming Lin
NPI 1912144288
$3,808.20
in general payments reported to CMS, 2019-2025
14 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $887 · 2022: $936 · 2023: $689 · 2024: $908 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,255.94 | 2021-2024 | Xarelto |
| Pfizer INC. | $715.35 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $639.42 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $337.66 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $243.75 | 2022-2025 | Farxiga, Lokelma, Wainua |
| Abbvie INC. | $194.82 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $144.00 | 2021-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.44 | 2021-2024 | Lifevest |
| Ferring Pharmaceuticals INC. | $51.25 | 2023-2024 | Rebyota |
| Bridgebio Pharma, INC. | $47.55 | 2025 | Attruby |
| Recordati_rare_diseases_inc. | $39.93 | 2025 | Isturisa |
| Mallinckrodt Hospital Products INC. | $30.53 | 2025 | Terlivaz |
| Boston Scientific Corporation | $30.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.47 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.